Skip to main content
John Welch, MD, Oncology, Saint Louis, MO

JohnSuttonWelchMD

Oncology Saint Louis, MO

Associate Professor, Internal Medicine, Division of Oncology, Washington University in St. Louis School of Medicine

Dr. Welch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Welch's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 314-454-8339
    Fax+1 314-454-5656

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2010
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2004 - 2006
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 2004

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2007 - 2025
  • American Board of Internal Medicine Medical Oncology
  • National Board of Physicians and Surgeons Internal Medicine
  • National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

  • Elected Member ASCI, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • TP53 Immunohistochemistry Correlates TP53 Mutation Status and Clearance in Decitabine-Treated Patients with Myeloid Malignancies  
    John S Welch, Eric J Duncavage, Haematologica
  • Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution  
    John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology

Abstracts/Posters

  • Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of T...
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • The Ugly: p53-Mutated Acute Myeloid Leukemia—Can It Be Solved? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Notable Launches New Clinical Study with Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance
    Notable Launches New Clinical Study with Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and ResistanceAugust 6th, 2020
  • $11.5 Million Supports Innovation in Leukemia Research
    $11.5 Million Supports Innovation in Leukemia ResearchNovember 6th, 2018
  • $11.5 Million Supports Innovation in Leukemia Research
    $11.5 Million Supports Innovation in Leukemia ResearchNovember 6th, 2018
  • Join now to see all

Other Languages

  • German